nach oben

Cancer and Metastasis Reviews

Erschienen in:

10.08.2018

Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer

verfasst von: Kasturi Chatterjee, Sayantan Jana, Preety Choudhary, Snehasikta Swarnakar

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

Cancer development and metastasis are associated to perturbation in metabolic functions of tumor cells and surrounding inflammatory and stromal cell responses. Eicosanoids and lipid mediators, in this regard, attract potential attention during cancer development. Eicosanoids, which include prostaglandin, prostacyclin, thromboxane, and leukotriene, are synthesized from arachidonic acid when cells are stimulated by stress, cytokines, or other growth factors. However, the underlying mechanism of eicosanoids in cancer development, specially their interactions with proto-oncogene factors in tumor microenvironment, remain unexplored. On the other hand, matrix metalloproteinases (MMPs) are a group of zinc-dependent endopeptidases which are involved in degradation of different extracellular matrix (ECM) proteins. MMPs are associated with different physiological responses, including embryogenesis, vasculogenesis, and cellular remodeling, as well as different disease pathogenesis. Induced MMP responses are especially associated with cancer metastasis and secondary tumor development through proteolytic cleavage of several ECM and non-ECM proteins. Although both eicosanoids and MMPs are involved with cancer progression and metastasis, the interrelation between these two molecules are less explored. The present review discusses relevant studies that connect eicosanoids and MMPs and highlight the crosstalk between them offering novel therapeutic approach in cancer treatment.

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193. https://doi.org/10.1038/nrc2809.PubMedPubMedCentralCrossRef

Wallace, J. M. (2002). Nutritional and botanical modulation of the inflammatory cascade--eicosanoids, cyclooxygenases, and lipoxygenases--as an adjunct in cancer therapy. Integrative Cancer Therapies, 1(1), 7–37; discussion 37. https://doi.org/10.1177/153473540200100102.PubMedCrossRef

Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141(1), 52–67. https://doi.org/10.1016/j.cell.2010.03.015.PubMedPubMedCentralCrossRef

Swarnakar, S., Paul, S., Singh, L. P., & Reiter, R. J. (2011). Matrix metalloproteinases in health and disease: regulation by melatonin. Journal of Pineal Research, 50(1), 8–20. https://doi.org/10.1111/j.1600-079X.2010.00812.x.PubMedCrossRef

Smyth, E. M., Grosser, T., Wang, M., Yu, Y., & FitzGerald, G. A. (2009). Prostanoids in health and disease. Journal of Lipid Research, 50(Suppl), S423–S428. https://doi.org/10.1194/jlr.R800094-JLR200.PubMedPubMedCentralCrossRef

Wang, D., & Dubois, R. N. (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 29(6), 781–788. https://doi.org/10.1038/onc.2009.421.PubMedCrossRef

Schneider, C., & Pozzi, A. (2011). Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Reviews, 30(3–4), 277–294. https://doi.org/10.1007/s10555-011-9310-3.PubMedPubMedCentralCrossRef

Funk, C. D. (2001). rostaglandins and leukotrienes: advances in eicosanoid biology. Science, 294(5548), 1871–1875. https://doi.org/10.1126/science.294.5548.1871.PubMedCrossRef

Serhan, C. N. (2011). The resolution of inflammation: the devil in the flask and in the details. The FASEB Journal, 25(5), 1441–1448. https://doi.org/10.1096/fj.11-0502ufm.PubMedPubMedCentralCrossRef

10.

Krishnamoorthy, S., & Honn, K. V. (2008). Eicosanoids in tumor progression and metastasis. Sub-Cellular Biochemistry, 49, 145–168. https://doi.org/10.1007/978-1-4020-8831-5_6.PubMedCrossRef

11.

Nozawa, H., Chiu, C., & Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12493–12498. https://doi.org/10.1073/pnas.0601807103.PubMedPubMedCentralCrossRef

12.

Wang, D., Wang, H., Shi, Q., Katkuri, S., Walhi, W., Desvergne, B., et al. (2004). Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell, 6(3), 285–295. https://doi.org/10.1016/j.ccr.2004.08.011.PubMedCrossRef

13.

Chizzolini, C., Chicheportiche, R., Alvarez, M., de Rham, C., Roux-Lombard, P., Ferrari-Lacraz, S., et al. (2008). Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood, 112(9), 3696–3703. https://doi.org/10.1182/blood-2008-05-155408.PubMedPubMedCentralCrossRef

14.

Boniface, K., Bak-Jensen, K. S., Li, Y., Blumenschein, W. M., McGeachy, M. J., McClanahan, T. K., et al. (2009). Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. The Journal of Experimental Medicine, 206(3), 535–548. https://doi.org/10.1084/jem.20082293.PubMedPubMedCentralCrossRef

15.

Scandella, E., Men, Y., Gillessen, S., Forster, R., & Groettrup, M. (2002). Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 100(4), 1354–1361. https://doi.org/10.1182/blood-2001-11-0017.PubMedCrossRef

16.

Wang, D., Buchanan, F. G., Wang, H., Dey, S. K., & DuBois, R. N. (2005). Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Research, 65(5), 1822–1829. https://doi.org/10.1158/0008-5472.Can-04-3671.PubMedCrossRef

17.

Krysan, K., Reckamp, K. L., Dalwadi, H., Sharma, S., Rozengurt, E., Dohadwala, M., et al. (2005). Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Research, 65(14), 6275–6281. https://doi.org/10.1158/0008-5472.Can-05-0216.PubMedCrossRef

18.

Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., & Gutkind, J. S. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310(5753), 1504–1510. https://doi.org/10.1126/science.1116221.PubMedCrossRef

19.

Liou, J. Y., Ellent, D. P., Lee, S., Goldsby, J., Ko, B. S., Matijevic, N., et al. (2007). Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells, 25(5), 1096–1103. https://doi.org/10.1634/stemcells.2006-0505.PubMedCrossRef

20.

Ihara, A., Wada, K., Yoneda, M., Fujisawa, N., Takahashi, H., & Nakajima, A. (2007). Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. Journal of Pharmacological Sciences, 103(1), 24–32.PubMedCrossRef

21.

Tong, W. G., Ding, X. Z., Talamonti, M. S., Bell, R. H., & Adrian, T. E. (2005). LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochemical and Biophysical Research Communications, 335(3), 949–956. https://doi.org/10.1016/j.bbrc.2005.07.166.PubMedCrossRef

22.

Buchanan, F. G., Gorden, D. L., Matta, P., Shi, Q., Matrisian, L. M., & DuBois, R. N. (2006). Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 103(5), 1492–1497. https://doi.org/10.1073/pnas.0510562103.PubMedPubMedCentralCrossRef

23.

Ito, H., Duxbury, M., Benoit, E., Clancy, T. E., Zinner, M. J., Ashley, S. W., et al. (2004). Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Research, 64(20), 7439–7446. https://doi.org/10.1158/0008-5472.Can-04-1177.PubMedCrossRef

24.

Qualtrough, D., Kaidi, A., Chell, S., Jabbour, H. N., Williams, A. C., & Paraskeva, C. (2007). Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. International Journal of Cancer, 121(4), 734–740. https://doi.org/10.1002/ijc.22755.PubMedPubMedCentralCrossRef

25.

Del Prete, A., Shao, W. H., Mitola, S., Santoro, G., Sozzani, S., & Haribabu, B. (2007). Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood, 109(2), 626–631. https://doi.org/10.1182/blood-2006-02-003665.PubMedPubMedCentralCrossRef

26.

Woo, C. H., You, H. J., Cho, S. H., Eom, Y. W., Chun, J. S., Yoo, Y. J., et al. (2002). Leukotriene B(4) stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. The Journal of Biological Chemistry, 277(10), 8572–8578. https://doi.org/10.1074/jbc.M104766200.PubMedCrossRef

27.

Kamiyama, M., Pozzi, A., Yang, L., DeBusk, L. M., Breyer, R. M., & Lin, P. C. (2006). EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene, 25(53), 7019–7028. https://doi.org/10.1038/sj.onc.1209694.PubMedCrossRef

28.

Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 101(2), 591–596. https://doi.org/10.1073/pnas.2535911100.PubMedCrossRef

29.

Jana, S., Chatterjee, K., Ray, A. K., DasMahapatra, P., & Swarnakar, S. (2016). Regulation of matrix metalloproteinase-2 activity by COX-2-PGE2-pAKT axis promotes angiogenesis in endometriosis. PLoS One, 11(10), e0163540. https://doi.org/10.1371/journal.pone.0163540.PubMedPubMedCentralCrossRef

30.

Jain, S., Chakraborty, G., Raja, R., Kale, S., & Kundu, G. C. (2008). Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Research, 68(19), 7750–7759. https://doi.org/10.1158/0008-5472.Can-07-6689.PubMedCrossRef

31.

Spinella, F., Rosano, L., Di Castro, V., Natali, P. G., & Bagnato, A. (2004). Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. The Journal of Biological Chemistry, 279(45), 46700–46705. https://doi.org/10.1074/jbc.M408584200.PubMedCrossRef

32.

Wang, D., Wang, H., Brown, J., Daikoku, T., Ning, W., Shi, Q., et al. (2006). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. The Journal of Experimental Medicine, 203(4), 941–951. https://doi.org/10.1084/jem.20052124.PubMedPubMedCentralCrossRef

33.

Dormond, O., Bezzi, M., Mariotti, A., & Ruegg, C. (2002). Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. The Journal of Biological Chemistry, 277(48), 45838–45846. https://doi.org/10.1074/jbc.M209213200.PubMedCrossRef

34.

Salcedo, R., Zhang, X., Young, H. A., Michael, N., Wasserman, K., Ma, W. H., et al. (2003). Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood, 102(6), 1966–1977. https://doi.org/10.1182/blood-2002-11-3400.PubMedCrossRef

35.

Sales, K. J., List, T., Boddy, S. C., Williams, A. R., Anderson, R. A., Naor, Z., et al. (2005). A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Research, 65(17), 7707–7716. https://doi.org/10.1158/0008-5472.Can-05-0101.PubMedPubMedCentralCrossRef

36.

Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C., & Marnett, L. J. (1999). Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Research, 59(18), 4574–4577.PubMed

37.

Zeddou, M., Greimers, R., de Valensart, N., Nayjib, B., Tasken, K., Boniver, J., et al. (2005). Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochemical Pharmacology, 70(5), 714–724. https://doi.org/10.1016/j.bcp.2005.05.015.PubMedCrossRef

38.

Baratelli, F., Lin, Y., Zhu, L., Yang, S. C., Heuze-Vourc'h, N., Zeng, G., et al. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. Journal of Immunology, 175(3), 1483–1490.CrossRef

39.

Verma, S., Kesh, K., Ganguly, N., Jana, S., & Swarnakar, S. (2014). Matrix metalloproteinases and gastrointestinal cancers: impacts of dietary antioxidants. World Journal of Biological Chemistry, 5(3), 355–376. https://doi.org/10.4331/wjbc.v5.i3.355.PubMedPubMedCentralCrossRef

40.

Swarnakar, S., & Jana, S. (2018). Matrix metalloproteinase. In S. Choi (Ed.), Encyclopedia of Signaling Molecules (2nd ed., pp. 3162–3162). Cham: Springer International Publishing.

41.

Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 69(3), 562–573. https://doi.org/10.1016/j.cardiores.2005.12.002.PubMedCrossRef

42.

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer, 2(3), 161–174. https://doi.org/10.1038/nrc745.PubMedCrossRef

43.

Ha, H. Y., Moon, H. B., Nam, M. S., Lee, J. W., Ryoo, Z. Y., Lee, T. H., et al. (2001). Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Research, 61(3), 984–990.PubMed

44.

Sternlicht, M. D., Lochter, A., Sympson, C. J., Huey, B., Rougier, J. P., Gray, J. W., et al. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell, 98(2), 137–146.PubMedPubMedCentralCrossRef

45.

Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology, 17, 463–516. https://doi.org/10.1146/annurev.cellbio.17.1.463.PubMedPubMedCentralCrossRef

46.

Deryugina, E. I., & Quigley, J. P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Reviews, 25(1), 9–34. https://doi.org/10.1007/s10555-006-7886-9.PubMedCrossRef

47.

Ichikawa, Y., Ishikawa, T., Momiyama, N., Kamiyama, M., Sakurada, H., Matsuyama, R., et al. (2006). Matrilysin (MMP-7) degrades VE-cadherin and accelerates accumulation of beta-catenin in the nucleus of human umbilical vein endothelial cells. Oncology Reports, 15(2), 311–315.PubMed

48.

Zheng, G., Lyons, J. G., Tan, T. K., Wang, Y., Hsu, T.-T., Min, D., et al. (2009). Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-β1 in renal tubular epithelial cells. The American Journal of Pathology, 175(2), 580–591. https://doi.org/10.2353/ajpath.2009.080983.PubMedPubMedCentralCrossRef

49.

Chatterjee, K., Jana, S., DasMahapatra, P., & Swarnakar, S. (2018). EGFR-mediated matrix metalloproteinase-7 up-regulation promotes epithelial-mesenchymal transition via ERK1-AP1 axis during ovarian endometriosis progression. The FASEB Journal, fj201701382RR. https://doi.org/10.1096/fj.201701382RR.

50.

Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., & Klagsbrun, M. (1997). Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. The Journal of Biological Chemistry, 272(50), 31730–31737.PubMedCrossRef

51.

Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., et al. (1998). An essential role for ectodomain shedding in mammalian development. Science, 282(5392), 1281–1284.PubMedCrossRef

52.

Vargo-Gogola, T., Crawford, H. C., Fingleton, B., & Matrisian, L. M. (2002). Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Archives of Biochemistry and Biophysics, 408(2), 155–161.PubMedCrossRef

53.

Jana, S., Paul, S., & Swarnakar, S. (2012). Curcumin as anti-endometriotic agent: implication of MMP-3 and intrinsic apoptotic pathway. Biochemical Pharmacology, 83(6), 797–804. https://doi.org/10.1016/j.bcp.2011.12.030.PubMedCrossRef

54.

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2(10), 737–744.PubMedPubMedCentralCrossRef

55.

Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. The Journal of Cell Biology, 169(4), 681–691. https://doi.org/10.1083/jcb.200409115.PubMedPubMedCentralCrossRef

56.

Sheu, B. C., Hsu, S. M., Ho, H. N., Lien, H. C., Huang, S. C., & Lin, R. H. (2001). A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Research, 61(1), 237–242.PubMed

57.

Yu, Q., & Stamenkovic, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes & Development, 14(2), 163–176.

58.

Gorelik, L., & Flavell, R. A. (2001). Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nature Medicine, 7(10), 1118–1122.PubMedCrossRef

59.

O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79(2), 315–328.PubMedCrossRef

60.

Patterson, B. C., & Sang, Q. A. (1997). Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). Journal of Biological Chemistry, 272(46), 28823–28825. https://doi.org/10.1074/jbc.272.46.28823.PubMedCrossRef

61.

Heljasvaara, R., Nyberg, P., Luostarinen, J., Parikka, M., Heikkila, P., Rehn, M., et al. (2005). Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Experimental Cell Research, 307(2), 292–304. https://doi.org/10.1016/j.yexcr.2005.03.021.PubMedCrossRef

62.

Hamano, Y. (2003). Physiological levels of tumstatin, a fragment of collagen IV [alpha]3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via [alpha]V [beta]3 integrin. Cancer Cell, 3, 589–601.PubMedPubMedCentralCrossRef

63.

Derynck, R., Akhurst, R. J., & Balmain, A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nature Genetics, 29(2), 117–129. https://doi.org/10.1038/ng1001-117.PubMedCrossRef

64.

Wang, X., & Lin, Y. (2008). Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacologica Sinica, 29(11), 1275–1288. https://doi.org/10.1111/j.1745-7254.2008.00889.x.PubMedPubMedCentralCrossRef

65.

Overall, C. M., & Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews. Cancer, 2(9), 657–672. https://doi.org/10.1038/nrc884.PubMedCrossRef

66.

Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., & Buckels, J. A. (2001). Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. Journal of Clinical Oncology, 19(15), 3447–3455. https://doi.org/10.1200/jco.2001.19.15.3447.PubMedCrossRef

67.

Cathcart, J., Pulkoski-Gross, A., & Cao, J. (2015). Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes & Diseases, 2(1), 26–34. https://doi.org/10.1016/j.gendis.2014.12.002.CrossRef

68.

Hu, J., Van den Steen, P. E., Sang, Q. X., & Opdenakker, G. (2007). Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Reviews. Drug Discovery, 6(6), 480–498. https://doi.org/10.1038/nrd2308.PubMedCrossRef

69.

Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1–4), 27–36. https://doi.org/10.1016/j.prostaglandins.2011.08.004.CrossRef

70.

Ishikawa, T. O., & Herschman, H. R. (2010). Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis, 31(4), 729–736. https://doi.org/10.1093/carcin/bgq002.PubMedPubMedCentralCrossRef

71.

Pavlovic, S., Du, B., Sakamoto, K., Khan, K. M., Natarajan, C., Breyer, R. M., et al. (2006). Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. The Journal of Biological Chemistry, 281(6), 3321–3328. https://doi.org/10.1074/jbc.M506846200.PubMedCrossRef

72.

Itatsu, K., Sasaki, M., Yamaguchi, J., Ohira, S., Ishikawa, A., Ikeda, H., et al. (2009). Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. The American Journal of Pathology, 174(3), 829–841. https://doi.org/10.2353/ajpath.2009.080012.PubMedPubMedCentralCrossRef

73.

Yen, J. H., Kocieda, V. P., Jing, H., & Ganea, D. (2011). Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation. The Journal of Biological Chemistry, 286(45), 38913–38923. https://doi.org/10.1074/jbc.M111.252932.PubMedPubMedCentralCrossRef

74.

Hsu, H. H., Hu, W. S., Lin, Y. M., Kuo, W. W., Chen, L. M., Chen, W. K., et al. (2011). JNK suppression is essential for 17beta-estradiol inhibits prostaglandin E2-induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells. Journal of Biomedical Science, 18, 61. https://doi.org/10.1186/1423-0127-18-61.PubMedPubMedCentralCrossRef

75.

Zahner, G., Harendza, S., Muller, E., Wolf, G., Thaiss, F., & Stahl, R. A. (1997). Prostaglandin E2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells. Kidney International, 51(4), 1116–1123.PubMedCrossRef

76.

Choi, Y. A., Lee, D. J., Lim, H. K., Jeong, J. H., Sonn, J. K., Kang, S. S., et al. (2004). Interleukin-1beta stimulates matrix metalloproteinase-2 expression via a prostaglandin E2-dependent mechanism in human chondrocytes. Experimental & Molecular Medicine, 36(3), 226–232. https://doi.org/10.1038/emm.2004.31.CrossRef

77.

Sato, T., Konomi, K., Fujii, R., Aono, H., Aratani, S., Yagishita, N., et al. (2011). Prostaglandin EP2 receptor signalling inhibits the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes. Annals of the Rheumatic Diseases, 70(1), 221–226. https://doi.org/10.1136/ard.2009.118620.PubMedCrossRef

78.

Fernandez-Patron, C., & Leung, D. (2015). Emergence of a metalloproteinase/phospholipase A2 axis of systemic inflammation. Metalloproteinases in Medicine, 2, 29–38. https://doi.org/10.2147/mnm.S48748.PubMedPubMedCentralCrossRef

79.

Hernandez-Anzaldo, S., Berry, E., Brglez, V., Leung, D., Yun, T. J., Lee, J. S., et al. (2015). Identification of a novel heart-liver axis: matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate lipid metabolism and inflammation in the liver. Journal of the American Heart Association, 4(11). https://doi.org/10.1161/jaha.115.002553.

80.

Weinreb, R. N., Kashiwagi, K., Kashiwagi, F., Tsukahara, S., & Lindsey, J. D. (1997). Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Investigative Ophthalmology & Visual Science, 38(13), 2772–2780.

81.

Li, X., & Tai, H. H. (2012). Increased expression of matrix metalloproteinases mediates thromboxane A2-induced invasion in lung cancer cells. Current Cancer Drug Targets, 12(6), 703–715.PubMedCrossRef

82.

Hartney, J. M., Gustafson, C. E., Bowler, R. P., Pelanda, R., & Torres, R. M. (2011). Thromboxane receptor signaling is required for fibronectin-induced matrix metalloproteinase 9 production by human and murine macrophages and is attenuated by the Arhgef1 molecule. The Journal of Biological Chemistry, 286(52), 44521–44531. https://doi.org/10.1074/jbc.M111.282772.PubMedPubMedCentralCrossRef

83.

Kummer, N. T., Nowicki, T. S., Azzi, J. P., Reyes, I., Iacob, C., Xie, S., et al. (2012). Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction. Journal of Cellular Biochemistry, 113(6), 1998–2008. https://doi.org/10.1002/jcb.24069.PubMedPubMedCentralCrossRef

84.

Hennig, R., Kehl, T., Noor, S., Ding, X. Z., Rao, S. M., Bergmann, F., et al. (2007). 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia, 9(11), 917–926.PubMedPubMedCentralCrossRef

85.

Ichiyama, T., Kajimoto, M., Hasegawa, M., Hashimoto, K., Matsubara, T., & Furukawa, S. (2007). Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clinical and Experimental Allergy, 37(4), 608–614. https://doi.org/10.1111/j.1365-2222.2007.02692.x.PubMedCrossRef

86.

Rajah, R., Nunn, S. E., Herrick, D. J., Grunstein, M. M., & Cohen, P. (1996). Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. The American Journal of Physiology, 271(6 Pt 1), L1014–L1022. https://doi.org/10.1152/ajplung.1996.271.6.L1014.PubMedCrossRef

87.

Piromkraipak, P., Sangpairoj, K., Tirakotai, W., Chaithirayanon, K., Unchern, S., Supavilai, P., et al. (2018). Cysteinyl leukotriene receptor antagonists inhibit migration, invasion, and expression of MMP-2/9 in human glioblastoma. Cellular and Molecular Neurobiology, 38(2), 559–573. https://doi.org/10.1007/s10571-017-0507-z.PubMedCrossRef

88.

Chandrasekharan, J. A., & Sharma-Walia, N. (2015). Lipoxins: nature’s way to resolve inflammation. Journal of Inflammation Research, 8, 181–192. https://doi.org/10.2147/jir.S90380.PubMedPubMedCentralCrossRef

89.

Zong, L., Li, J., Chen, X., Chen, K., Li, W., Li, X., et al. (2016). Lipoxin A4 attenuates cell invasion by inhibiting ROS/ERK/MMP pathway in pancreatic cancer. Oxidative Medicine and Cellular Longevity, 2016, 6815727. https://doi.org/10.1155/2016/6815727.PubMedCrossRef

90.

Chen, Q. H., Zhou, W. D., Pu, D. M., Huang, Q. S., Li, T., & Chen, Q. X. (2010). 15-Epi-lipoxin A(4) inhibits the progression of endometriosis in a murine model. Fertility and Sterility, 93(5), 1440–1447. https://doi.org/10.1016/j.fertnstert.2009.01.107.PubMedCrossRef

91.

Leppert, D., Hauser, S. L., Kishiyama, J. L., An, S., Zeng, L., & Goetzl, E. J. (1995). Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. The FASEB Journal, 9(14), 1473–1481.PubMedCrossRef

92.

Yu, W., Chen, L., Yang, Y. Q., Falck, J. R., Guo, A. M., Li, Y., et al. (2011). Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 68(3), 619–629. https://doi.org/10.1007/s00280-010-1521-8.PubMedCrossRef

93.

Moshal, K. S., Zeldin, D. C., Sithu, S. D., Sen, U., Tyagi, N., Kumar, M., et al. (2008). Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. Journal of Cellular Physiology, 215(3), 771–781. https://doi.org/10.1002/jcp.21356.PubMedPubMedCentralCrossRef

94.

Michaelis, U. R., Fisslthaler, B., Barbosa-Sicard, E., Falck, J. R., Fleming, I., & Busse, R. (2005). Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. Journal of Cell Science, 118(Pt 23), 5489–5498. https://doi.org/10.1242/jcs.02674.PubMedCrossRef

95.

Calder, P. C. (2013). Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? British Journal of Clinical Pharmacology, 75(3), 645–662. https://doi.org/10.1111/j.1365-2125.2012.04374.x.PubMedPubMedCentralCrossRef

96.

Taguchi, A., Kawana, K., Tomio, K., Yamashita, A., Isobe, Y., Nagasaka, K., et al. (2014). Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. PLoS One, 9(2), e89605. https://doi.org/10.1371/journal.pone.0089605.PubMedPubMedCentralCrossRef

Titel: Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer
verfasst von: Kasturi Chatterjee
Sayantan Jana
Preety Choudhary
Snehasikta Swarnakar
Publikationsdatum: 10.08.2018
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9756-7

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications

Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer

Bioactive lipid metabolism in platelet “first responder” and cancer biology

Targeting lipid mediators in cancer biology

Eicosanoids in prostate cancer

Targeting the enzymes involved in arachidonic acid metabolism to improve radiotherapy

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie